DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).

Abstract

Background: CT‐P13 subcutaneous (SC) infliximab formulation showed comparable efficacy and safety with CT‐P13 intravenous (IV) infliximab in inflammatory bowel disease (IBD)1 and rheumatoid arthritis2 This study aimed to demonstrate the superiority of CT‐P13 SC over placebo as maintenance therapy after induction therapy of CT‐P13 IV in patient with Crohn's disease (CD) Methods: Moderately to severely active CD patients with Crohn's disease activity index (CDAI) score 220 to 450 and simplified endoscopic activity score for Crohn's disease (SES‐CD) of >6 points for ileal‐colonic CD or >4 points including ulcer score from at least 1 segment for ileal CD or colonic CD were enrolled LIBERTY‐CD study (NCT03945019) and treated with open‐label CT‐P13 IV 5 mg/kg at Weeks 0, 2 and 6 as induction therapy. At Week 10, patients who had a clinical response were randomised (2:1) to receive either CT‐P13 SC 120 mg (CT‐P13 SC) or placebo every 2 weeks up to Week 54. At Week 54, clinical remission and endoscopic response were assessed as co‐primary endpoints. Clinical response, clinical remission (alternative definition) endoscopic remission, and corticosteroid‐free remission were assessed at Week 54 as key secondary endpoint. Safety was evaluated up to Week 54 Results: A total of 396 patients were enrolled and 343 patients (86.6%) were randomised (231 in CT‐P13 SC arm and 112 in placebo arm) at Week 10. At Week 54, the clinical remission rate was greater in CT‐P13 SC arm than placebo arm (62.3% and 32.1% respectively with P <0.0001). The endoscopic response rate was also greater in CT‐P13 arm than placebo arm (51.1% and 17.9% respectively, with P <0.0001). CT‐P13 SC also had significantly greater efficacy on key secondary endpoints results compared to placebo arm (Table 1). Safety profiles were generally comparable between CT‐P13 SC and placebo arms, but a single death was reported during the maintenance phase (Table 2) Conclusion: CT‐P13 SC was more effective than placebo in clinical remission, endoscopic response, clinical response, clinical remission (alternative definition), endoscopic remission, and corticosteroid‐free remission at Week 54. No new safety concerns were found during treatment of CT‐P13 SC. These results demonstrate that maintenance therapy with CT‐P13 SC provides both a robust clinical benefit and the convenience of SC administration to moderately to severely active CD patients.